Abstract
Background: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. Patients and methods: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. Results: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9%) had ≥1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55-9.39). Conclusions: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 295-300 |
| Number of pages | 6 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 59 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2007 Mar 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)
Cite this
}
Irofulven as first line therapy in recurrent or metastatic gastric cancer : A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). / Yeo, W.; Boyer, M.; Chung, H. C.; Ong, S. Y.K.; Lim, R.; Zee, Benny; Ma, B.; Lam, K. C.; Mo, F. K.F.; Ng, E. K.W.; Ho, R.; Clarke, S.; Roh, J. K.; Beale, P.; Rha, S. Y.; Jeung, H. C.; Soo, R.; Goh, B. C.; Chan, A. T.C.
In: Cancer Chemotherapy and Pharmacology, Vol. 59, No. 3, 01.03.2007, p. 295-300.Research output: Contribution to journal › Article
TY - JOUR
T1 - Irofulven as first line therapy in recurrent or metastatic gastric cancer
T2 - A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
AU - Yeo, W.
AU - Boyer, M.
AU - Chung, H. C.
AU - Ong, S. Y.K.
AU - Lim, R.
AU - Zee, Benny
AU - Ma, B.
AU - Lam, K. C.
AU - Mo, F. K.F.
AU - Ng, E. K.W.
AU - Ho, R.
AU - Clarke, S.
AU - Roh, J. K.
AU - Beale, P.
AU - Rha, S. Y.
AU - Jeung, H. C.
AU - Soo, R.
AU - Goh, B. C.
AU - Chan, A. T.C.
PY - 2007/3/1
Y1 - 2007/3/1
N2 - Background: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. Patients and methods: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. Results: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9%) had ≥1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55-9.39). Conclusions: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.
AB - Background: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. Patients and methods: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. Results: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9%) had ≥1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55-9.39). Conclusions: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.
UR - http://www.scopus.com/inward/record.url?scp=33845873055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845873055&partnerID=8YFLogxK
U2 - 10.1007/s00280-006-0270-1
DO - 10.1007/s00280-006-0270-1
M3 - Article
C2 - 16783579
AN - SCOPUS:33845873055
VL - 59
SP - 295
EP - 300
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 3
ER -